Truist Financial
ALXN

Truist Financial’s Alexion Pharmaceuticals ALXN Stock Holding History

Truist Financial’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-18,823
Closed -$3.46M – 2873
2021
Q2 		$3.46M Sell
18,823
-7,950
-30% -$1.36M 0.01% 1034
2021
Q1 		$4.09M Sell
26,773
-41,122
-61% -$6.36M 0.01% 926
2020
Q4 		$10.6M Buy
67,895
+45,866
+208% +$5.89M 0.02% 582
2020
Q3 		$2.52M Sell
22,029
-103,220
-82% -$11.1M 0.01% 985
2020
Q2 		$14.1M Sell
125,249
-3,292
-3% -$350K 0.03% 446
2020
Q1 		$11.5M Buy
128,541
+107,265
+504% +$10.5M 0.03% 461
2019
Q4 		$2.3M Buy
21,276
+15,740
+284% +$1.68M ﹤0.01% 1070
2019
Q3 		$543K Sell
5,536
-704
-11% -$79.4K 0.01% 555
2019
Q2 		$817K Buy
6,240
+41
+0.7% +$5.28K 0.01% 489
2019
Q1 		$838K Buy
6,199
+340
+6% +$42.3K 0.02% 491
2018
Q4 		$571K Sell
5,859
-1,218
-17% -$144K 0.01% 536
2018
Q3 		$984K Buy
7,077
+428
+6% +$53.7K 0.02% 479
2018
Q2 		$825K Sell
6,649
-101
-1% -$11.8K 0.02% 506
2018
Q1 		$752K Buy
6,750
+798
+13% +$95.4K 0.01% 508
2017
Q4 		$712K Sell
5,952
-219
-4% -$26.7K 0.01% 530
2017
Q3 		$866K Buy
6,171
+463
+8% +$62.9K 0.02% 491
2017
Q2 		$695K Buy
5,708
+364
+7% +$42.4K 0.01% 520
2017
Q1 		$648K Buy
+5,344
New +$689K 0.01% 539

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Truist Financial's ALXN Position: Q3 2021 in Review

Truist Financial sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 18,823 shares — an estimated $3.46M sold.

Truist Financial first reported a position in ALXN in Q1 2017 and held it in 18 quarters. The position peaked at $14.1M in Q2 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Truist Financial reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Truist Financial sold 18,823 Alexion Pharmaceuticals shares in Q3 2021, an estimated $3.46M.
  • Truist Financial first reported a position in Alexion Pharmaceuticals in Q1 2017 and held it in 18 quarters.
  • Truist Financial's Alexion Pharmaceuticals position peaked at $14.1M in Q2 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Truist Financial's 13F filing for Q3 2021, filed 5 Nov 2021.